Synthes gets FDA warning on bone void filler use
This article was originally published in Clinica
Executive Summary
Synthes has received an FDA warning letter for allegedly promoting two orthopaedic products for unapproved spinal application. The two products in question - the Norian XR Calcium Phosphate Bone Void filler and Norian SRS Bone Void Filler - are not intended to treat vertebral compression fractures, such as are common in patients with osteoarthritis because it is not known whether the products might cause an embolism, the FDA notes.
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.